Google
Trusted Resources: Community Center
Online support, community stories, financial assistance
Alnylam Pharmaceuticals – Linkedin
Alnylam is the world’s leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases.
Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today’s medicines.
myBinderRelated Content
-
Clarification on Prothena AFFIRM and CAEL-101 Global Trials: Muriel Finkel – ASG Webinar 11/13https://www.youtube.com/watch?v=NrEjyVeJ...
-
Prothena and the AFFIRM-AL Study: Ansgar Conrad – ASG Webinar 9/13https://www.youtube.com/watch?v=NrEjyVeJ...
-
Prothena Reports Results From the Phase 3 VITAL Amyloidosis Study of NEOD001 (Birtamimab) in AL AmyloidosisProthena Corporation PLC, a clinical-sta...
-
Eidos Therapeutics Initiates ATTRibute-CM, a Phase 3 Study of AG10 in ATTR-CM with Registrational 12-month EndpointEidos Therapeutics, Inc., today announce...
-
Prof. Philip Hawkins, FMedSciProf. Philip Hawkins is a Professor of M...
-
Tarek Ashour, MDTarek Ashour is a Nephrologist at Clevel...
-
Ronald S. Go, MDRonald S. Go earned his degree in Medici...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
